FDA REFORM DEBATE MAY SPUR "MORE INFORMED" OVERSIGHT OF FDA BY CONGRESS, SENATE STAFFER SAYS; PDUFA REAUTHORIZATION HAS SET FIVE-YEAR CYCLE FOR FD&C ACT REVIEW
This article was originally published in The Gray Sheet
The FDA Modernization Act's prescription drug user fee sunset creates a "five-year cycle" for review of the FD&C Act, Senate Labor & Human Resources Committee Health Policy Advisor Jay Hawkins told the annual Food & Drug Law Institute meeting Dec. 9 in Washington, D.C.
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.